News

Net Loss of Suven Life Sciences reported to Rs 127.61 crore in the quarter ended June 2026 as against net loss of Rs 51.52 crore during the previous quarter ended June 2025. Sales rose 90.91% to Rs 3.57 crore in the quarter ended June 2026 as against Rs 1.87 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales3.571.87 91 OPM %-3711.48-2713.90 - PBDT-125.46-50.15 -150 PBT-127.61-51.52 -148 NP-127.61-51.52 -148 Powered by Capital Market - Live News

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 6 August 2026.

Suven Life Sciences announced that the 37th Annual General Meeting(AGM) of the company will be held on 25 August 2026.

Net Loss of Suven Life Sciences reported to Rs 45.60 crore in the quarter ended March 2026 as against net loss of Rs 43.94 crore during the previous quarter ended March 2025. Sales rose 3.40% to Rs 1.52 crore in the quarter ended March 2026 as against Rs 1.47 crore during the previous quarter ended March 2025.For the full year,net loss reported to Rs 276.34 crore in the year ended March 2026 as against net loss of Rs 160.75 crore during the previous year ended March 2025. Sales rose 6.76% to Rs 7.11 crore in the year ended March 2026 as against Rs 6.66 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1.521.47 3 7.116.66 7 OPM %-3331.58-2980.95 --4001.41-2489.19 - PBDT-44.01-42.60 -3 -270.73-154.92 -75 PBT-45.60-43.94 -4 -276.34-160.75 -72 NP-45.60-43.94 -4 -276.34-160.75 -72 Powered by Capital Market - Live News

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 13 May 2026.